News Room

The first Covid-19 vaccine candidate went into the arms of volunteers in Seattle in March 2020. It was an mRNA vaccine from Moderna. The mRNA candidate from BioNTech and Pfizer followed in April. By December 2020, these two had become the first vaccines to be approved by the US Food and Drug Administration (FDA). Hot on their heels are rivals based on adenovirus vectors from AstraZeneca and Johnson & Johnson, as well as Sputnik V from Russia. 

As more people get vaccinated, doctors say we need to start thinking about moving vaccines from mass vaccination sites to health care facilities, such as doctors' offices.

Disruptions in the global high-tech supply chain spell bad news for Chevy Silverados and Samsung phones alike.

The transport of people and goods changed drastically due to the pandemic. The question remains, however, if it will remain changed and, if so, in what ways. 

Tens of millions of people across the U.S. have received a coronavirus vaccine. So far, the majority of doses have been either the Moderna or Pfizer vaccine, both of which use mRNA to generate an immune response. These gene-based vaccines have been in the works for decades, but this is the first time they have been used widely in people.